PUBLIC COMPANY
saveBeacon Therapeutics Ltd
updated 2mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
- phase2A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
- phase2A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
- phase2A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
- phase2Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
- phase2Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
🐶 Hiring Signal
News
- Beacon eye gene therapy hits mark in late-stage studyBeacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.biopharma_dive · 9d ago
- Beacon says gene therapy succeeds in key trial of rare eye disease XLRPBeacon Therapeutics has succeeded in a genetic eye disease where large drugmakers have failed, including Johnson & Johnson and Biogen. On Monday, Beacon said its gene therapy laru-zova for X-linked…endpoints · 9d ago
- Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapyBeacon Therapeutics has found the light in a rare vision loss disease that has left larger companies in the dark. The biotech’s gene therapy for X-linked retinitis pigmentosa (XLRP) successfully im…fiercebiotech · 10d ago
comments(0)
5-min edit window · permanent after that